Market Newsdesk

July 26, 2021 6:03 am

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

PR Newswire

NEW YORK, July 26, 2021 /PRNewswire/ –BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on August 05, 2021.

BrainStorm’s Chief Executive Officer, Chaim Lebovits, will present a corporate update after which participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, President and Chief Medical Officer, Stacy Lindborg, PhD, Executive Vice President and Global Head of Clinical Research, David Setboun, PharmD, MBA, Executive Vice President and Chief Operating Officer, and Preetam Shah, PhD, MBA, Executive Vice President and Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: [email protected]. Questions should be submitted by 5:00 p.m. Eastern Time on Wednesday, August 4, 2021.

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:

Toll Free: 888-506-0062
International: 973-528-0011
Entry Code: 298566

Webcast URL: https://www.webcaster4.com/Webcast/Page/2354/41929

Those interested in listening to the conference call live via the internet may do so by using the webcast link above or by visiting the “Investors & Media” page of BrainStorm’s website at https://ir.brainstorm-cell.com/overview and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Numbers:

Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 41929

About NurOwn®

The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).

For more information, visit the company’s website at www.brainstorm-cell.com.

Contacts
Investor Relations:
John Mullaly
LifeSci Advisors, LLC
Phone: +1 617-430-7485
[email protected]

Media:

Paul Tyahla

SmithSolve
Phone: + 1.973.713.3768
[email protected]

Logo – https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/brainstorm-to-announce-second-quarter-financial-results-and-provide-a-corporate-update-301340822.html

SOURCE Brainstorm Cell Therapeutics Inc

July 26, 2021 6:03 am

New Local Partnership Sees uCloudlink’s PaaS and SaaS Ecosystem Expansion in Southeast Asia

PR Newswire

HONG KONG, July 26, 2021 /PRNewswire/ — UCLOUDLINK GROUP INC. (NASDAQ: UCL, “uCloudlink”), the world’s first and leading mobile data traffic sharing marketplace, is further strengthening its footprint in Southeast Asia with a new local partnership with FuXing Kitchen Equipment Inc.(“FuXing”), a leading kitchenware manufacturer in the Philippines.

Under the agreement, uCloudlink will provide its mobile broadband (MBB) products and services to FuXing. The partnership marks the first time that uCloudlink’s cooperation with the household appliances industry and solidifies its position in mobile broadband data connectivity services.

uCloudlink’s cooperation with FuXing follows a string of successful partnership agreements in Southeast Asia, including expanded cooperation with Shore-Access Marine Consultancy Co., Ltd. (“Shore Access”) and a new alliance with PT Harapan Karunia Makmur (“HKM”). As an international communication service provider based in the Philippines, Shore Access signed a contract with uCloudlink earlier this year to distribute its products and connectivity services. uCloudlink has also established a partnership with HKM, a large information and communication technology distributor based in Jakarta, to manufacture and distribute uCloudlink’s MBB-related devices and data connectivity services throughout Indonesia.

uCloudlink’s PaaS and SaaS ecosystem integrates and intelligently allocates the resources of various data service suppliers, terminal suppliers and application developers to enhance the user experience of data connection, which creates unique value for its partners and users, and strengthens its competitive advantage in the global arena.

uCloudlink has amassed a wealth of global resources through partners and users as a result of uCloudlink 1.0 business (international mobile data connectivity services) and uCloudlink 2.0 business (local mobile data connectivity services). Such resources have formed the basis of uCloudlink’s PaaS and SaaS ecosystem. Through its ecosystem, uCloudlink builds upon its resources to provide SaaS application services, data management, equipment sales and rentals and user traffic management to mobile network operators (MNOs), mobile virtual network operators (MVNOs), and business partners.

uCloudlink’s innovative HyperConn™ technology solution paves the way for further development of uCloudlink’s business such as opportunities in new industries, including those with high requirements for connection quality, such as education, video conferencing, emergency response, surveillance and etc.

uCloudlink is continuing to optimize its user experience. Leveraging uCloudlink’s PaaS and SaaS platforms, HyperConn™ is an affordable one-stop data connection service that facilitates “Single Operator Entry Point to Access Global all Available Networks” for better network connectivity.

About UCLOUDLINK GROUP INC.

uCloudlink is the world’s first and leading mobile data traffic sharing marketplace, pioneering the sharing economy business model for the telecommunications industry. The Company’s products and services deliver unique value propositions to mobile data users, handset and smart-hardware companies, mobile virtual network operators (MVNOs) and mobile network operators (MNOs). Leveraging its innovative cloud SIM technology and architecture, the Company has redefined the mobile data connectivity experience by allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace, while providing reliable connectivity, high speeds and competitive pricing.

Contact:
Carina Cheung
[email protected]
Tel: （852）21806111

View original content:https://www.prnewswire.com/news-releases/new-local-partnership-sees-ucloudlinks-paas-and-saas-ecosystem-expansion-in-southeast-asia-301340110.html

SOURCE UCLOUDLINK GROUP INC.

July 26, 2021 6:03 am

FPT Industrial Bourbon-Lancy plant awarded World Class Manufacturing Gold Medal

London, July 26, 2021

The FPT Industrial engine manufacturing facility in Bourbon-Lancy, France, has achieved Gold Level designation in the World Class Manufacturing (WCM) program. It is now the third CNH Industrial N.V. (NYSE: CNHI/MI: CNHI) site, after IVECO’s Madrid and Valladolid plants in Spain, to be awarded this status.

The factory specializes in the manufacture of the Cursor engine series which offers 77 technical variations and over 5,700 different options. It has a production capacity of some 80,000 engines a year, and a workforce of close to 1,200 people. The Bourbon-Lancy site is recognized as a center of excellence for both diesel and natural gas engines manufacturing a range of bespoke engines to meet the specific requirements of a range of applications from On and Off Highway vehicles to marine and power generation.

The Bourbon-Lancy plant is well known in the region for its commitment to sustainability. In addition to being the home of the most successful natural gas-powered engines on the market, the plant has also implemented a number of projects that focus on minimizing the impact of industrial activities and protecting the biodiversity of its surrounding environment.

World Class Manufacturing is one of the global manufacturing industry’s highest standards for the integrated management of manufacturing plants and processes. It is a pillar-structured system based on continuous improvement, designed to eliminate waste and loss from the production process by identifying objectives such as zero injuries, zero defects, zero breakdowns and zero waste. To certify improvements, a system of periodic third-party audits evaluates all of the WCM pillars, forming an overall score for each plant that is the basis for three achievement levels: Bronze, Silver and Gold.

The WCM audit in Bourbon-Lancy noted progress and consistency across a variety of both manufacturing and managerial areas including Cost Deployment and Autonomous Maintenance Workplace Organization leading to the Gold Level designation.

CNH Industrial

N.V.

(NYSE: CNHI /M
I
: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and
Steyr
for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and
Heuliez
Bus for buses and coaches; Iveco Astra for quarry and construction vehicles;
Magirus
for firefighting vehicles; Iveco
Defence
Vehicles for
defence
and civil protection; and FPT Industrial for engines and transmissions.
More information can be found on the corporate website:

www.cnhindustrial.com

Sign up for corporate news alerts from the CNH Industrial Newsroom:

bit.ly/media-

cnhindustrial

-subscribe

Media
contact
:

Laura Overall
Corporate Communications Manager
CNH Industrial
Tel. +44 (0)2077 660 338
E-mail: [email protected]
www.cnhindustrial.com

Attachments

July 26, 2021 6:03 am

RadNet, Inc. Announces Date of its Second Quarter 2021 Financial Results Conference Call

LOS ANGELES, July 26, 2021 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its second quarter 2021 financial results on Monday, August 9^th, 2021 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors are invited to listen to RadNet’s conference call by dialing 888-394-8218. International callers can dial 646-828-8193. There will also be simultaneous and archived webcasts available at http://public.viavid.com/index.php?id=146019. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 3277272.

About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 346 owned and/or operated outpatient imaging centers. RadNet’s markets include California, Maryland, Delaware, New Jersey, New York, Florida and Arizona. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 8,300 employees. For more information, visit http://www.radnet.com.

CONTACTS:

RadNet, Inc.

Mark Stolper
Executive Vice President and Chief Financial Officer
310-445-2800

July 26, 2021 6:03 am

AYVAKIT® (avapritinib) Companion Diagnostic Test Enters Priority Review and Approval Process in China

BEIJING, July 26, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), today announced that its AYVAKIT^® (avapritinib) companion diagnostic (CDx) kit, developed in partnership with CStone Pharmaceuticals (“CStone”, HKEX: 2616) has entered the priority review and approval process under the National Medical Products Administration (NMPA) in China.

The test kit is the first companion diagnostic product developed in China to go through the NMPA’s accelerated review channel. This channel expedites the review of qualified medical devices that are deemed urgent and necessary, so that they can be applied sooner in clinical settings.

During the process, the Center for Medical Device Evaluation (CMDE) under the NMPA carries out a priority technical review, working closely with the company to expedite the process. Provincial food and drug authorities also make the review of the product a priority throughout their registered quality management systems. The product then goes through a priority administrative process under the NMPA, which approves the product at the end.

Gastrointestinal stromal tumor (GIST) patients with human platelet-derived growth factor receptor alpha (PDGFRA) gene mutations lack effective treatment drugs. AYVAKIT^® has demonstrated remarkable efficacy and acceptable safety in Chinese patients with unresectable or metastatic GIST harboring PDGFRA exon 18 mutations, including D842V.

As a proprietary companion diagnostic for AYVAKIT^®, the CDx kit can be used to effectively detect PDGFRA D842V gene mutation in GIST patients, providing accurate molecular diagnosis for targeted drug application which may translate into durable clinical benefits for these patients.

The AYVAKIT^® CDx test kit is based on a real-time PCR fluorescent probe, specific primers, Taqman probes, and highly specific Taq enzymes to detect gene mutations. This enables the test kit to detect mutations with higher specificity and sensitivity in DNA samples. A clinical study utilizing the test kit was carried out at the Beijing Cancer Hospital, Harbin Medical University Cancer Hospital and Shanghai Tenth People’s Hospital, demonstrating data on par with that of the Sanger sequencing method and exhibiting total coincidence rates of over 99%.

“I am very pleased that the AYVAKIT^® companion diagnostics test kit has entered the NMPA priority review and approval process, distinguishing itself through innovative, original technology and strong performance data. The development of such companion diagnostics products can enable doctors to choose more suitable, targeted drugs for patients, while lowering the costs of drug development, accelerating the development process, and improving drug safety and effectiveness. Genetron Health is committed to exploring more innovative pathways for the development of new drugs and companion diagnostics, providing more choices for patient care,” said Sizhen Wang, Co-Founder and CEO of Genetron Health.

“Precision medicine is one of CStone’s core strategies. As the world’s first therapeutic approved for GIST based on driver mutations, AYVAKIT^® was approved by the NMPA in March 2021 after passing the NMPA’s priority review process. Molecular diagnosis has become imperative for GIST patients. I am very pleased that the AYVAKIT^® companion diagnostic kit has also entered the priority review process. I look forward to the early approval of this diagnostic kit, so that more GIST patients in China can benefit from precision treatment,” said Dr. Archie Tse, Chief Scientific Officer of CStone.

About AYVAKIT^® (avapritinib)

AYVAKIT^® (avapritinib) is a kinase inhibitor approved by the China National Medical Products Administration (NMPA) for the treatment of adults with unresectable or metastatic GIST harboring the PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

The U.S. Food and Drug Administration (FDA) has approved AYVAKITTM for the treatment of two indications: adults with advanced systemic mastocytosis (SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL), and adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

This medicine is approved by the European Commission under the brand name AYVAKYT^® for the treatment of adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation.

AYVAKIT^®/AYVAKYT^® is not approved for the treatment of any other indication in the U.S., Europe or Greater China, or for any indication in any other jurisdiction by any other health authority.

Blueprint Medicines is developing AYVAKIT^® globally for the treatment of advanced and non-advanced SM. The FDA granted breakthrough therapy designation to AYVAKIT^® for the treatment of advanced SM, including the subtypes of ASM, SM-AHN, and MCL, and for the treatment of moderate to severe indolent SM.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

About CStone

CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan. CStone’s vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: www.cstonepharma.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the priority review and approval process in China, the collaboration with CStone for the joint development of a CDx test for avapritinib are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
Hoki Luk
Email: [email protected]
Phone: +1 (408) 891-9255

Media Relations Contact
Yanrong Zhao
Genetron Health
Email:[email protected]

July 26, 2021 6:03 am

Agora, Inc. to Report Second Quarter 2021 Financial Results on August 9, 2021

SANTA CLARA, Calif., July 26, 2021 (GLOBE NEWSWIRE) — Agora, Inc. (NASDAQ: API) (“Agora”), a pioneer and leading platform for real-time engagement APIs, announced today that it will release financial results for the second quarter ended June 30, 2021 after the close of U.S. markets on August 9, 2021. Agora will host a conference call to discuss the financial results at 6 p.m. Pacific Time / 9:00 p.m. Eastern Time on the same day. Details for the conference call are as follows:

Event title: Agora, Inc. 2Q 2021 Financial Results

Conference ID: 8897989

Direct Event online registration: http://apac.directeventreg.com/registration/event/8897989

Please register in advance of the conference using the link provided above. Upon registering, you will be provided with participant dial-in numbers, Direct Event passcode and unique registrant ID.

A digital recording of the conference call will be available for replay two hours after the call’s completion (dial-in number: US 18554525696, International +61 2 81990299; same conference ID as shown above).

Please visit Agora’s investor relations website at https://investor.agora.io/investor-relations on August 9, 2021 to view the earnings release and accompanying slides prior to the conference call.

About Agora

Agora’s mission is to make real-time engagement ubiquitous, allowing everyone to interact with anyone, in any app, anytime and anywhere. Agora’s cloud platform provides developers simple, flexible and powerful application programming interfaces, or APIs, to embed real-time video and voice engagement functionalities into their applications. Agora maintains dual headquarters in Shanghai, China and Santa Clara, California.

Investor Contact:
Fionna Chen
[email protected]

Media Contact:
Suzanne Nguyen
[email protected]

July 26, 2021 6:03 am

The World’s First 0.49mm Fine-Pitch Mini-LED Display Panel Using 36 Pixel-in-1 MiniLED πLED Package.

The World’s First 0.49mm Fine-Pitch Mini-LED Display Panel Using 36 Pixel-in-1 MiniLED πLED Package.

CHUNAN, Taiwan–(BUSINESS WIRE)–
TSLC Corporation, a vertically integrated LED system manufacturer, introduced the world’s first 0.49mm fine-pitch direct-lit display using 36 pixels-in-1 πLED package (Pixels Interconnected LED or πLED). The display is utilized proprietary πLED technology from SemiLEDs Corporation and drivers made by Raffar Technology Corporation. Unlike other fine-pitch miniLED displays in the market, TSLC’s display panel uses SMT process to populate the pixels, enabling exceptional production throughput and efficient repair rate.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005318/en/

Top (left) and bottom (right) view of ΠLED. (Photo: Business Wire)

TSLC’s 36 pixels-in-1 SMT compatible package is a quantum leap technology from the 16pixels package that was introduced 3 years ago by SemiLEDs eliminating the needs for die and wire bonding. Within a footprint of 2.89mm x 2.89mm, the package consists of 36 pixels; each pixel consists of a red, green and blue LED chip. A total of 108 LED chips are interconnected via micron-level precision technology. Since the LEDs are already connected electrically, the number of solder pad electrically connecting each πLED package to the PCB main board is reduced from 144 to 24. The reduction of solder pad enables bigger solder pads that are more spaced out, significantly decrease the difficulties during SMT process and increase solder reliability due to larger pad areas. πLED pixels are arranged in a 6 by 6 pixels configuration and delivered via tape and reel ready for SMT. The increase in pixel count per package will enable TSLC to improve SMT process by 2.25 times. The technology will also allow easier repair procedures than conventional chip-on-board (CoB) technology.

“3 years ago, we introduced the 4 by 4, 16 pixels package, steering the market from CoB to SMT process. Currently, we see other companies adapting the 16 pixels solution simply because it is a more realistic way to mass produce. TSLC had been persistent on this SMT path and is at the forefront by introducing the 36 pixels package. We will open up more opportunities in the high-end fine-pitch display market” Explained Peter Pon, the Director of Sales and Marketing Department of TSLC Corporation.

The πLED technology is provided by SemiLEDs Corporation and is available for licensing and purchasing through TSLC.

About TSLC Corporation

TSLC Corporation is a leading LED manufacturer and technology developer located in Hsinchu Science Park, Chu-Nan site, Taiwan. TSLC has more than 10 years of experience in the LED industry specializing in LEDs in the visible, infrared and ultraviolet spectrum. The company focuses on specialized products like miniLED and ultraviolet LED.

Forward Looking Statements

This press release contains statements that may constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to, any projections of future revenues, income, margins or other financial information; any statements about historical results that may suggest trends for TSLC’s business; any statements of the plans, strategies and objectives of management for future operations; any statements of expectation or belief regarding recovery of the LED industry, market opportunities and other future events or technology developments; any statements regarding TSLC’s position to capitalize on any market opportunities; and any statements of assumptions underlying any of the foregoing. These forward-looking statements are based on current expectations, estimates, forecasts and projections of future TSLC’s or industry performance based on management’s judgment, beliefs, current trends and market conditions and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. TSLC undertakes no intent or obligation to publicly update or revise any of these forward looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005318/en/

[email protected]

TSLC Corporation

+886-37-586788

KEYWORDS: Taiwan Asia Pacific

INDUSTRY KEYWORDS: Technology Hardware Other Technology Consumer Electronics

MEDIA:

Photo

0.49mm pitch display build with 36pixels MiniLED πLED package (Photo: Business Wire)

Photo

Top (left) and bottom (right) view of ΠLED. (Photo: Business Wire)

July 26, 2021 6:03 am

ModivCare Expands Personal Care Segment with Acquisition of CareFinders

ModivCare Expands Personal Care Segment with Acquisition of CareFinders

— Adds greater scale to ModivCare’s leading personal care platform established with the foundational acquisition of Simplura Health Group —

DENVER–(BUSINESS WIRE)–
ModivCare Inc. (“ModivCare” or the “Company”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions focused on improving patient outcomes, today announced that the Company has signed a merger agreement to acquire CareFinders Total Care LLC (“CareFinders”).

CareFinders is a personal care provider in the Northeast, with a scaled presence in New Jersey, Pennsylvania, and Connecticut. CareFinders delivers approximately 10 million hours of care annually to over 7,500 patients through its more than 6,200 caregivers. CareFinders’ annual revenue is approximately $200 million, pro forma for recent acquisitions, generated primarily from Medicaid and Managed Care Organization payors. During the pandemic, ModivCare partnered with CareFinders to remove the barrier of transportation for its caregivers by providing more than 85,000 rides, which greatly assisted CareFinders in continuing to care for their patients in the home.

Under the terms of the agreement, ModivCare will acquire 100 percent of the equity interests in CareFinders for a purchase price of $340 million (subject to customary purchase price adjustments), inclusive of estimated $34 million of net present value tax attributes generated by the transaction, implying a net purchase price of $306 million. ModivCare intends to fund the transaction through a combination of cash on hand and the Company’s credit facility. The transaction is expected to close in the third quarter of 2021, subject to customary closing conditions.

Once the acquisition of CareFinders is completed, ModivCare’s personal care segment is expected to include nearly 16,000 caregivers across 7 states, expecting to provide approximately 30 million hours of care to approximately 18,000 patients annually.

“ModivCare is leading the transformation to better connect people with care, through transportation, personal care, and nutritional meal delivery,” said Daniel E. Greenleaf, President and Chief Executive Officer of ModivCare. “The acquisition of CareFinders broadens access to in-home personal care solutions for patients and supports our strategy to expand on our personal care platform. We are evaluating an expanse of opportunities to continue this exciting and profitable growth. As we expand our footprint, we believe we will drive significant value for our patients, partners, and shareholders.”

Mr. Greenleaf further commented, “Creating healthier communities means providing connections to more reliable care and being the partner of choice for caregivers, and for the payors and states we serve. With the acquisition of CareFinders, we are incredibly excited about advancing health equity for those who need it most.”

Dave Middleton, President and Chief Executive Officer of ModivCare’s personal care segment, added, “The combination of our companies further strengthens our presence in the Northeast and complements our existing personal care capabilities. We are better together – making a meaningful difference one patient, and one moment of care at a time.”

Heath Sampson, Chief Financial Officer of ModivCare, added, “The transaction is projected to deliver immediate earnings accretion to ModivCare. Furthermore, in addition to an exciting long-term trajectory, we expect near-term momentum from the business as COVID-19 pressures recede and recent rate increases are implemented.”

Jim Robinson, Chief Executive Officer of CareFinders added, “CareFinders has been dedicated to improving the lives of our patients and creating a uniquely rewarding environment for caregivers throughout our history, so it is a natural fit for us to join the ModivCare family of integrated supportive care solutions. We look forward to partnering with the entire ModivCare team to leverage the power of technology and our shared Total Care philosophy to continue to influence healthier outcomes and change lives for the better.”

Jefferies LLC is serving as exclusive financial advisor to ModivCare and Gibson, Dunn & Crutcher LLP is serving as ModivCare’s legal advisor. Moelis & Company LLC and J.P. Morgan Securities LLC are serving as financial advisors to CareFinders and Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as CareFinders’ legal advisor.

Conference Call

ModivCare will hold a conference call to discuss the acquisition of CareFinders on Monday, July 26, 2021, at 8:30 a.m. ET.

To access the conference call by phone, please dial:

US toll-free: 1 877-423-9820
International: 1 201-493-6749

The webcast and accompanying presentation can be accessed on the Company’s website: https://investors.modivcare.com/events-presentations/default.aspx.

The webcast also can be accessed here.

The conference call will be archived on the Company’s website.

Forward-Looking Statements

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are frequently identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” and similar words indicating possible future expectations, events or actions. In addition, statements that are not historical statements of fact should also be considered forward-looking statements. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about the Company’s business and the Company’s industry, and are not guarantees of the Company’s future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein.

The Company has provided additional information in its Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) for the fiscal year ended December 31, 2020 and subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made and are expressly qualified in their entirety by the cautionary statements set forth herein and in our other filings with the SEC. We undertake no obligation to update or revise any forward- looking statements contained in this release, whether as a result of new information, future events or otherwise, except as required by applicable law.

About ModivCare

ModivCare Inc. (“ModivCare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal and home care, and nutritional meal delivery. ModivCare also holds a minority equity interest in CCHN Group Holdings, Inc. and its subsidiaries (“Matrix Medical Network”), which partners with leading health plans and providers nationally, delivering a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance. To learn more about ModivCare, please visit www.modivcare.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005212/en/

Media:

Kate Zerone

Senior Manager, Communications

[email protected]

Investors:

The Equity Group

Kalle Ahl, CFA

[email protected]

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Hospitals General Health Health Practice Management

MEDIA:

Logo

July 26, 2021 6:03 am

The New Home Company Reports Selected Preliminary 2021 Second Quarter Results

The New Home Company Reports Selected Preliminary 2021 Second Quarter Results

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–
The New Home Company Inc. (NYSE: NWHM) today announced selected preliminary results for the 2021 second quarter in connection with meetings with investors. These estimated results are preliminary and unaudited.

Preliminary 2021 Second Quarter Financial Highlights (Estimated Results)

Net new orders of 187 as compared to 164 in the 2020 second quarter, a 14% increase
Monthly sales absorption of 3.3 per community as compared to 2.2 per community in the 2020 second quarter, a 50% increase
Home sales revenue of $135.9 million as compared to $77.8 million for the 2020 second quarter, a 75% increase
- Deliveries increased 98% and average selling price decreased 12% to $666,000 consistent with the Company’s shift to more affordable price points, including a significant increase in deliveries from its Arizona operation
Homes in backlog of 632 homes, representing $439.4 million in backlog value as compared to 235 homes, representing $168.8 million at the end of the 2020 second quarter
Ending cash balance of $117.3 million, a $31.7 million increase as compared to June 30, 2020
Total liquidity of $177.3 million, including $60 million in availability under its unsecured revolving credit facility
Total debt of $280.6 million as of June 30, 2021 as compared to $295.1 million as of June 30, 2020

We have provided the above preliminary estimated financials results because our financial closing procedures for the three months ended June 30, 2021 are not yet complete. The preliminary estimated financial information set forth above does not represent a comprehensive statement of our results of operations or financial condition as of or for the three months ended June 30, 2021 and is based solely on information available to us as of the date of this press release. Our results of operations and financial condition as of and for the three months ended June 30, 2021 may vary from our current expectations and may be different from the information described above as our quarterly financial statement preparation process is not yet complete and additional developments and adjustments may arise between now and the time the financial statements and other disclosures for this period are finalized, including all disclosures required by GAAP. In addition, these preliminary estimates are not necessarily indicative of the results to be achieved for the remainder of 2021 or in any future period. There can be no assurance that these estimates will be realized, and estimates are subject to risks and uncertainties, many of which are not within our control. The foregoing information should not be viewed as a substitute for full financial statements prepared in accordance with GAAP or as a measure of performance. Accordingly, you should not place undue reliance on such preliminary estimated financial information. Our preliminary estimated financial results are forward-looking statements.

About The New Home Company

NEW HOME is a publicly traded company listed on the New York Stock Exchange under the symbol “NWHM.” It is a new generation homebuilder focused on the design, construction and sale of innovative and consumer-driven homes in major metropolitan areas within select growth markets in California, Arizona and Colorado. For more information about the Company and its new home developments, please visit the Company’s website at www.NWHM.com.

Forward-Looking Statements

Various statements contained in this press release, including those that express a belief, anticipation, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements. Such statements include the statements regarding current business conditions. These forward-looking statements may include projections and estimates concerning our revenues, community counts and openings, the timing and success of specific projects, our ability to execute our strategic growth objectives, gross margins, other projected results, income, earnings per share, joint ventures and capital spending. Our forward-looking statements are generally accompanied by words such as “estimate,” “should,” “project,” “predict,” “believe,” “expect,” “intend,” “anticipate,” “potential,” “plan,” “goal,” “will,” “guidance,” “target,” “forecast,” or other words that convey the uncertainty of future events or outcomes. The forward-looking statements in this press release speak only as of the date of this release, and we disclaim any obligation to update these statements unless required by law, and we caution you not to rely on them unduly. We have based these forward-looking statements on our current expectations and assumptions about future events. While our management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control. The following factors, among others, may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements: a pandemic, epidemic, or outbreak of infectious disease or similar threat, and the response to such event by government agencies and authorities, adverse impacts due to the COVID-19 pandemic, including a recession in the U.S., which could include, among other things, a significant decrease in demand for our homes or consumer confidence generally with respect to purchasing a home, the impact of legislation designed to provide economic relief from a recession, the inability of employees to work and of customers to visit our communities due to government movement restrictions or illness, disruptions in our supply chain, our inability to access capital markets due to lack of liquidity in the economy resulting from the responses to the COVID-19 pandemic, inconsistencies in the classification of homebuilding as an essential business, recognition of charges which may be material for inventory impairments or land option contract abandonments; economic changes either nationally or in the markets in which we operate, including declines in employment, volatility of mortgage interest rates and inflation; a downturn in the homebuilding industry; changes in sales conditions, including home prices, in the markets where we build homes; our significant amount of debt and the impact of restrictive covenants in our debt agreements; our ability to repay our debt as it comes due; changes in our credit rating or outlook; volatility and uncertainty in the credit markets and broader financial markets; our business and investment strategy including our plans to sell more affordably priced homes; availability of land to acquire and our ability to acquire such land on favorable terms or at all; our liquidity and availability, terms and deployment of capital; changes in margin; write-downs; shortages of or increased prices for labor, land or raw materials used in housing construction; adverse weather conditions and natural disasters (including wild fires and mudslides); our concentration in California; issues concerning our joint venture partnerships; the cost and availability of insurance and surety bonds; governmental regulation, including the impact of “slow growth” or similar initiatives; changes in, or the failure or inability to comply with, governmental laws and regulations; the timing of receipt of regulatory approvals and the opening of projects; delays in the land entitlement process, development, construction, or the opening of new home communities; litigation and warranty claims; the degree and nature of competition; the impact of recent accounting standards; availability of qualified personnel and our ability to retain our key personnel; and information technology failures and data security breaches, including issues involving increased reliance on technology due to critical business functions being done remotely because of COVID-19; and additional factors discussed under the sections captioned “Risk Factors” included in our annual report and other reports filed with the Securities and Exchange Commission. The Company reserves the right to make such updates from time to time by press release, periodic report or other method of public disclosure without the need for specific reference to this press release. No such update shall be deemed to indicate that other statements not addressed by such update remain correct or create an obligation to provide any other updates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005158/en/

Investor Relations | Drew Mackintosh | 949-382-7838 | [email protected]

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Residential Building & Real Estate Architecture Construction & Property

MEDIA:

Logo

July 26, 2021 6:03 am

Insulet to Present at Upcoming Investor Conferences

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.–(BUSINESS WIRE)–
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced that management will present at two upcoming virtual investor conferences:

The Canaccord 41^st Annual Growth Conference on Wednesday, August 11, 2021 at 11:00 a.m. (Eastern Time)
The UBS Genomics 2.0 and MedTech Innovations Summit on Thursday, August 12, 2021 at 4:00 p.m. (Eastern Time)

To listen to the live audio webcast of the presentation, please visit investors.insulet.com. A replay of the audio webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005023/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

[email protected]

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Technology Biotechnology Diabetes Health Other Health Pharmaceutical Other Science Other Technology Research Medical Devices General Health Hardware Science Consumer Electronics

MEDIA:

Logo